Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in NASH
NCT05842512Phase 2Recruiting
- Sponsor
- Polaris Group
- Start
- Sep 2023
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing ADI-PEG 20 with Placebo (2 arms). Primary endpoint: Absolute Change from Baseline in Hepatic Fat Fraction at 24 weeks. Started Sep 2023; status: recruiting.
02
Drugs
Pegargiminase
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05842512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842512.